ATACANA GROUP Inc.’s Post

📢 EASL 2024: Pioneering the Next Era in MASH Treatment! 🏥 We are eagerly awaiting the European Association for the Study of the Liver (EASL) Congress 2024! 🌍✨ We’ll be on the lookout for exciting updates from: 💊 Madrigal Pharmaceuticals' Resmetirom (Rezdiffra): how is the first and only approved MASH therapy setting new standards in liver health? What are the latest news on real-world evidence, non-invasive diagnostics, and patient quality of life improvements?🧬 🔬 New Data and Discussion around other Promising MoAs: •GLP-1 Analogs: Semaglutide (Novo Nordisk) and Tirzepatide’s (Eli Lily) •Glucagon/GLP-1 receptor dual agonists: Survodutide (BI) and Pemvidutide (Altimmune) •FGF-21 Analogs: Efruxifermin (Akero) and Pegozafermin (89bio) •Other MoAs: Sagimet’s Denifanstat (FASN inhibitor) and Ionis’s ION224 (DGAT2 inhibitor) 💡 What breakthrough in MASH treatment are you most excited to see at EASL 2024? Share your thoughts in the comments section below ✨ For more insights in the MASH space, 📥email us at info@atacana.com #EASL2024 #LiverHealth #MASH #NASH #PharmaInnovation #MedicalResearch #competitiveintelligence

📣 Discover another exciting session during the 10+1 Santorini Conference on May 24th at 09:00! Join our experts to exchange on « Pharmacogenomics: clinical translation - now and future – Part 1 » through four conferences: ⚪ Trends in precision medicine, pharmacogenetics as adjuvant in establishing a correct immunosuppressive therapy of kidney transplant, Sergio Bernardini ⚪ From Pharmacogenomics to Polygenic Risk Score (PRS) for Drug Response Prediction- Are We There Yet? Candan Hizel Perry ⚪An in vitro functional assay for determining CYP2D6 enzyme activity, Simone Vanoni ⚪Interindividual variability and pharmacogenomics: Possible ways forward, Munir Pirmohamed Final stretch to join us in Santorini from May 21st to 24th! ➡ https://lnkd.in/ewRNGanx #personalisedmedicine #chronicdisease #omics #pharmacology #pharmacogenomics

🌟 Highlights from the International Myeloma Society Conference in Rio 🇧🇷 Last week, we had the opportunity to attend the #IMS2024! The session 𝐌𝐑𝐃 𝐈𝐒 𝐀𝐍 𝐄𝐍𝐃 𝐏𝐎𝐈𝐍𝐓: 𝐎𝐔𝐑 𝐒𝐔𝐂𝐂𝐄𝐒𝐒 𝐒𝐓𝐎𝐑𝐘 🌟 highlighted the amazing work and data provided by the Myeloma Community that lead the ODAC (Oncologic Drugs Advisory Committee) of the FDA to acknowledge the use of MRD as an intermediate endpoint to support accelerated approval in 𝐍𝐃𝐌𝐌 and 𝐑𝐑𝐌𝐌. 🔬It also raised the need for high-sensitive, dynamic and non-invasive assessment of MRD. 👥 Connecting with patients, clinicians and pharma companies at IMS, we had great discussions sharing the added value of our 𝐂𝐥𝐨𝐧𝐨𝐭𝐲𝐩𝐢𝐜 𝐏𝐞𝐩𝐭𝐢𝐝𝐞𝐬 𝐌𝐚𝐬𝐬 𝐒𝐩𝐞𝐜𝐭𝐫𝐨𝐦𝐞𝐭𝐫𝐲 𝐭𝐞𝐬𝐭 for MRD monitoring in blood🩸. 𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐨𝐮𝐫 𝐭𝐞𝐚𝐦 💬 𝐭𝐨 𝐤𝐧𝐨𝐰 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐌-𝐢𝐧𝐒𝐢𝐠𝐡𝐭! Pauline Fontaine, Pharm.D., Ph.D., M.Res., Caroline Rougé Dubroc, Pharm.D., Vincent BONIFAY, Youssef Maakaroun 🔗𝐌-𝐢𝐧𝐒𝐢𝐠𝐡𝐭: https://lnkd.in/eK7nhu48 #Myeloma #MultipleMyeloma #MRD #MassSpectrometry #InnovationInHealthcare #Peptides #MInSight

#ICYMI 🔉 Our latest podcast episode of The Life Science Report is now live!     ➡️ Hepatology market dynamics over the past five years, including activity from Gilead Sciences, Novo Nordisk, Intercept Pharmaceuticals and CymaBay Therapeutics    ➡️ How treatment for primary biliary cholangitis, an autoimmune condition, went from a one to a three-product market ➡️ Payer monographs and what’s required for hepatology drugs    ➡️ The EMA recommendation earlier this month to revoke Ocaliva’s marketing authorization    ➡️ Which companies are active in the rare liver disease space and how they differentiate themselves    Listen to the full episode here: 🎧 https://bit.ly/3zu2Nfx     #PodcastAlert #Hepatology #AutoImmune #MarketInsights #BBLSA  

🌟 Exciting News from Kira Pharma! 🌟   We’re thrilled to share the long-term positive results of KP104 Phase 2 study with PNH naïve patients, presented at the EHA Congress 2024 in an oral presentation!   Key highlights from 18 patients treated with KP104 for up to 65 weeks, with 24-26 weeks of treatment time on Optimal Biological Dose (OBD): 🔹 100% (18/18) of patients achieved ≥2 g/dL hemoglobin increase. 🔹 6.6 g/dL (mean) hemoglobin increase from baseline. 🔹 89% (16/18) attained hemoglobin normalization (>12 g/dL) 🔹 94% (17/18) maintained LDH levels below 1.5x ULN. 🔹 100% (18/18) were free from RBC transfusions during the study. 🔹 Significant improvements in reticulocyte counts, bilirubin levels, and fatigue scores. 🔹 KP104 was safe and well-tolerated with no serious adverse events.   These results underscore KP104’s potential as an optimal first-line monotherapy for PNH to safely and effectively control both intravascular and extravascular hemolysis. Global Phase 3 studies are being planned to potentially establish KP104 as the new standard of care for PNH to address the existing unmet medical needs. #KiraPharma #EHA2024 #PNH #Biotech #Innovation #KP104 https://lnkd.in/edNh3Rus

Sagimet Biosciences reported Phase 2b data in metabolic-associated steatohepatitis (MASH)—also known as nonalcoholic steatohepatitis (#NASH). Findings show that denifanstat beat placebo on two key endpoints. The rate of resolution of #MASH without worsening of #fibrosis and with at least a two-point reduction in disease activity was 36% on denifanstat and 13% on placebo. Denifanstat is a FASN inhibitor, setting it apart from Madrigal Pharmaceuticals’ resmetirom. Sagimet plans to initiate a late-stage study of the drug in the second half of this year. #liver #liverdisease

𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐢𝐧 𝐉𝐚𝐩𝐚𝐧 𝐏𝐡𝐚𝐬𝐞 𝐈𝐈𝐈 𝐓𝐫𝐢𝐚𝐥 𝐨𝐟 𝐀𝐜𝐨𝐫𝐚𝐦𝐢𝐝𝐢𝐬 𝐟𝐨𝐫 𝐀𝐓𝐓𝐑-𝐂𝐌 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬 🌟 Exciting News in Medicine! 🌟 BridgeBio Pharma, Inc. (Nasdaq: BBIO) BridgeBio is thrilled to share positive results from the Japan Phase III trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The trial, conducted by Alexion, AstraZeneca AstraZeneca Rare Disease, demonstrated consistency with the global BridgeBio ATTRibute-CM Phase III trial. Key Highlights: Acoramidis well-tolerated in a 30-month single-arm study in Japanese patients. No safety concerns identified, and no mortality reported. Positive outcomes include improved survival, reduced cardiovascular-related hospitalizations, and enhanced functional measures. This significant advancement in treating ATTR-CM showcases the potential of acoramidis as a next-generation, oral, highly potent small molecule stabilizer of transthyretin (TTR). #CardiomyopathyTreatment #AcoramidisResults #HealthcareInnovation #BridgeBioPharma #ATTRCM #HeartHealth #ClinicalTrials

Came across this great read about the use of metabolomics in drug discovery. It is definitely a powerful tool that complements our traditional ways to examine and evaluate the favorability of drug candidates for therapeutic development and identify their mechanisms of action. At MAX BioPharma, in collaboration with scientists at Metaba, we have started to apply metabolomics in our drug discovery efforts and development of our oxysterol drug candidates for multiple indications including non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), atherosclerosis, and chronic inflammation. Large amounts of insightful information are derived from metabolomic studies, and hopefully soon we will begin to share our findings with the scientific community. #Oxysterol #Metabolomics #NASH #IPF #Atherosclerosis #Cysticfibrosis #Inflammation #MAXBioPharma #Metaba Philip Sell Metaba Jaejin (Joey) Lee Eric Michel, PhD https://lnkd.in/g_xdSU5Q

We are so happy to have these world renowned macular degeneration experts join the Aviceda family developing a drug that resolves overactivated chronic innate immune phagocytic retinal inflammation, the underlying cause of geographic atrophy, in patients with advanced dry AMD. The potential to repolarize inflammatory Microglia with AVD 104 to the neuroprotective subretinal microglial state identified by the Saban lab at Duke https://hubs.la/Q02j8cMC0 has the potential not only to halt progression of GA but rescue photoreceptors and RPE cells that have not already undergone irreversible apoptosis. The ability to rescue retinal cell and photoreceptor function was seen in a single intravitreal injection dose escalation trial of AVD 104 in patients with center involving bilateral GA patients.(SIGLEC part 1 trial) These patients had a dose dependent significant improvement in ETDRS BCVA which corroborated with multi focal ERG improvement and anatomic cessation of RPE cell loss over a follow up of 3 months . This degree of clinical efficacy resulting from AVD 104 have never been seen with any investigational drug tested or approved for GA and hold the promise of not only preventing vision loss but recovering visual function. AVD104 also represents a novel class of self associated molecular pattern mimetic designed to bind to Sialic acid Ig like lectin (SIGLEC ) family of receptors the most abundant checkpoint receptors in the immune system , which utilizes the ITIM/ITSM checkpoint pathway of PD1 (keytruda target) and which represents the main self receptor, the main pathway to prevent autoimmunity and a pathway used by cancers and infections to evade immune detection. In addition AVD 104 binds CFH as the requisite activator of the decay accelerating function of CFH. By physiologically abrogating the alternative pathway, the maintenance homeostatic role of complement can be restored versus disabled by current complement inhibitory strategies. Aviceda uses the immune systems natural immune controls to reign in age accelerated immune activation. Without these key clinical advisors, this promising novel therapy to treat the devastating condition of GA would never be realized. So please join me in welcoming theses critical advisors to the Aviceda journey.

𝐈𝐫𝐨𝐧𝐰𝐨𝐨𝐝 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐨𝐫 𝐀𝐩𝐫𝐚𝐠𝐥𝐮𝐭𝐢𝐝𝐞 𝐢𝐧 𝐆𝐈 𝐚𝐆𝐕𝐇𝐃 Ironwood Pharmaceuticals (Nasdaq: IRWD) Ironwood Pharmaceuticals announces positive Phase II results for apraglutide in patients with steroid-refractory gastrointestinal acute Graft-versus-Host Disease (SR GI aGVHD). Apraglutide, a next-generation GLP-2 analog, showed promising safety and tolerability in combination with standard therapy. Majority of patients responded to treatment by Day 28 and maintained response through Day 91. Dr. Robert Zeiser, Principal Investigator, highlights apraglutide's potential in managing acute GI GVHD. GI aGVHD is a life-threatening complication post HSCT, affecting a significant number of patients. Ironwood's Chief Medical Officer, Dr. Michael Shetzline Michael Shetzline, emphasizes apraglutide's role in addressing high unmet medical needs. Stay tuned for additional data from the STARGAZE trial at upcoming medical congresses. #GIHealth #GraftVersusHostDisease #Apraglutide #ClinicalTrial #MedicalResearch #Hematology #Immunotherapy #HSCT